UMIN-ICDR Clinical Trial

BACK TOP
UMIN-ICDR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000021991
Receipt No. R000025303
Scientific Title The effect and proper dose of unfractionated heparin after digital replantation: a prospective study
Date of disclosure of the study information 2016/04/21
Last modified on 2018/05/29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title The effect and proper dose of unfractionated heparin after digital replantation: a prospective study
Acronym The unfractionated heparin administration after digital replantation: a prospective study
Scientific Title The effect and proper dose of unfractionated heparin after digital replantation: a prospective study
Scientific Title:Acronym The unfractionated heparin administration after digital replantation: a prospective study
Region
Japan

Condition
Condition Digital amputations
Classification by specialty
Plastic surgery
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Investigation of the effect and proper dose of unfractionated heparin (UFH) after digital replantation
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Evaluation of the success rate at 2 weeks after replantation of amputated digits
Key secondary outcomes Evaluation of the partial success rate, severity of anemia, blood transfusion volume when needed, and presence or absence of infection.

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Single blind -participants are blinded
Control Dose comparison
Stratification YES
Dynamic allocation NO
Institution consideration
Blocking
Concealment Central registration

Intervention
No. of arms 3
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Group 1 is defined by UFH 0 units per day. Pre-observation period is defined as from the first outpatient consultation to completion of surgery. The onset of the study is defined to be the time of replantation of the digit with anastomosis of the vein. The follow-up period is approximately one month after surgery. The minimum and the maximum periods are defined as 2 weeks and 2 months, respectively, for all examination items. The observation period is defined in the same manner. Continuous intravenous infusion of prostaglandin preparation for 7 days at the rate of 120yg/day, postoperatively. Each item is evaluated three times by blood test at 6 hours, 3 days, and 7 days, postoperatively. Additional treatments are promptly planned and conducted when considered necessary. The best conceivable prevention, diagnosis, and treatment are to be offered, considering the results of this study. Hemoglobin is controlled to be 10 mg/dL or higher, postoperatively. UFH administration is suspended only when anemia is difficult to control, although UFH administration is to be continued for cases where blood transfusion is effective in improving the condition. When presence of infection is suspected, culture of the wound is to be immediately submitted, and appropriate antibiotics (first generation cephem) are administered, considering the epidermal normal bacteria flora as pathogenic bacteria (causative organisms).
Interventions/Control_2 Group 2 is defined by UFH 10,000 units per day. Continuous intravenous drip infusion of UFH is started from soon after surgery. The dose period is 7 days. Each item is evaluated three times by blood test at 6 hours, 3 days, and 7 days, postoperatively.Continuous intravenous infusion of prostaglandin preparation for 7 days at the rate of 120yg/day, postoperatively.
Interventions/Control_3 Group 3 is defined by UFH 15,000 units per day. Continuous intravenous drip infusion of UFH is started from soon after surgery. The dose period is 7 days. Each item is evaluated three times by blood test at 6 hours, 3 days, and 7 days, postoperatively. In Group 3, dosage of UFH is adjusted, and APTT is controlled to be 1.5 to 2.5-fold that of preoperative levels. Continuous intravenous infusion of prostaglandin preparation for 7 days at the rate of 120yg/day, postoperatively.
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1)Patients who have an amputated digit together with abnormal blood flow and seek replantation of the digit.
2)Patients who have undergone intraoperative anastomosis of the vein.
3)Patients who voluntarily give written consent to their participation in this study (or consent by the patient's family) after explanation and understanding of the study.
Key exclusion criteria 1) Patients who decide to withdraw their consent to participate.
2) Patients who have a history of hypersensitivity to UFH component.
3) Patients who have a history of thrombocytopenia caused by heparin.
4) are currently receiving oral administration of anticoagulants or anti-platelet agents.
5) Patients who have a history of blood diseases (such as idiopathic thrombocytopenic purpura.)
6) Patients who have severe hepatic diseases (with AST or ALT levels of 100 U/L or higher).
7) Patients who have severe renal disease (with BUN levels of 25 mg/dL or higher, or serum creatinine levels of 2.0 mg/dL or higher).
8) Patients who are pregnant or lactating.
Target sample size 165

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name AKIO NISHIJIMA
Organization New Tokyo Hospital
Division name Department of Plastic and Reconstructive Surgery
Zip code
Address 1271 Wanagaya, Matsudo City, Chiba 270-2232, Japan
TEL 0477118700
Email handbal1016@yahoo.co.jp

Public contact
Name of contact person
1st name
Middle name
Last name AKIO NISHIJIMA
Organization New Tokyo Hospital
Division name Department of Plastic and Reconstructive Surgery
Zip code
Address 1271 Wanagaya, Matsudo City, Chiba 270-2232, Japan
TEL 0477118700
Homepage URL
Email handbal1016@yahoo.co.jp

Sponsor
Institute New Tokyo Hospital
Institute
Department

Funding Source
Organization No
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor University of Tsukuba Hospital
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 新東京病院(千葉県)

Other administrative information
Date of disclosure of the study information
2016 Year 04 Month 21 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2015 Year 09 Month 01 Day
Date of IRB
Anticipated trial start date
2015 Year 09 Month 15 Day
Last follow-up date
2018 Year 05 Month 29 Day
Date of closure to data entry
2018 Year 05 Month 29 Day
Date trial data considered complete
2018 Year 05 Month 29 Day
Date analysis concluded
2018 Year 06 Month 30 Day

Other
Other related information

Management information
Registered date
2016 Year 04 Month 19 Day
Last modified on
2018 Year 05 Month 29 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000025303

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.